Sign up for our daily briefing

Make your busy days simpler with Axios AM/PM. Catch up on what's new and why it matters in just 5 minutes.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Catch up on the day's biggest business stories

Subscribe to Axios Closer for insights into the day’s business news and trends and why they matter

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Stay on top of the latest market trends

Subscribe to Axios Markets for the latest market trends and economic insights. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Sports news worthy of your time

Binge on the stats and stories that drive the sports world with Axios Sports. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Tech news worthy of your time

Get our smart take on technology from the Valley and D.C. with Axios Login. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Get the inside stories

Get an insider's guide to the new White House with Axios Sneak Peek. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Denver news?

Get a daily digest of the most important stories affecting your hometown with Axios Denver

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Des Moines news?

Get a daily digest of the most important stories affecting your hometown with Axios Des Moines

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Twin Cities news?

Get a daily digest of the most important stories affecting your hometown with Axios Twin Cities

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Tampa Bay news?

Get a daily digest of the most important stories affecting your hometown with Axios Tampa Bay

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Charlotte news?

Get a daily digest of the most important stories affecting your hometown with Axios Charlotte

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Nashville news?

Get a daily digest of the most important stories affecting your hometown with the Axios Nashville newsletter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Columbus news?

Get a daily digest of the most important stories affecting your hometown with the Axios Columbus newsletter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Dallas news?

Get a daily digest of the most important stories affecting your hometown with the Axios Dallas newsletter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Sign up for Axios NW Arkansas

Stay up-to-date on the most important and interesting stories affecting NW Arkansas, authored by local reporters

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Photo: Artur Widak/NurPhoto via Getty Images

Tens of thousands of Americans who stepped up to help test coronavirus vaccines through clinical trials are now stuck without a standard vaccine card to prove it.

State of play: Two vaccine candidates — created by Novavax and AstraZeneca, respectively — have clinical trial data suggesting they're effective, but have yet to be authorized for use in the U.S. That leaves clinical trial participants in a potentially tough spot.

The big picture: Businesses and governments are increasingly requiring people to be vaccinated in order to work and travel.

Between the lines: The situation is particularly confusing for participants in the Novavax trial, as it's not approved for use anywhere in the world. AstraZeneca's vaccine, on the other hand, is being used in countries around the globe.

  • The CDC's recommendations for fully vaccinated people apply to vaccines authorized for use in the U.S. as well as those that have been authorized by the World Health Organization, according to a CDC spokesperson.
  • That means they would apply to people who have received both shots of AstraZeneca, but not Novavax.

Zoom in: Albert Lewitinn participated in the Novavax trial and has since found out he received the actual vaccine, not a placebo.

  • But it's unclear whether his vaccine status will allow him to enter Spain and Israel, where he plans to travel in the coming weeks. He has a CDC card that identifies him as a clinical trial participant, but it's not the same as the ones received by everyone else.
  • He's thought about getting Johnson & Johnson's one-shot coronavirus vaccine, but isn't sure whether he should.
  • “I was doing it for the public interest. But turns out, I’m kind of in limbo," he said.

The CDC said COVID-19 vaccines are not interchangeable. The safety and effectiveness of receiving two different COVID-19 vaccines is still being studied.

  • "Also, no data are available on the safety or efficacy of receiving a COVID-19 vaccine currently authorized in the United States after receipt of a non-FDA-authorized COVID-19 vaccine," a CDC spokesman said.

What they're saying: Trial participants are eligible for modified CDC vaccination cards that state they have been vaccinated through a clinical trial and that the individual is to be considered fully vaccinated for public health purposes, Novavax said.

  • "Novavax firmly believes that clinical trial participants should not be disadvantaged with respect to providing proof of vaccination and we are actively supporting authorities working to provide proof of vaccination for all who volunteered in our pivotal Phase 3 clinical trials," the company added.

What we're watching: Employers' vaccine mandates or restrictions on unvaccinated employees could also be difficult for trial participants to navigate.

  • “There are bound to be bureaucracy problems until there’s a better understanding of where we are," said Cornell vaccine researcher and Novavax trial participant John Moore.
  • “I’ve received an HR email saying I’m not vaccinated. I’m not losing sleep over losing my job, but these situations do need sorting out via greater awareness.”

Go deeper

Oct 16, 2021 - Health

Pope Francis calls on companies to release COVID vaccine patents

Pope Francis. Photo: Massimo Valicchia/NurPhoto via Getty Images

Pope Francis called on pharmaceutical companies on Saturday to release patents to make COVID-19 vaccines more accessible to the poor, Reuters reports.

Why it matters: There is a stark divide between countries that have access to COVID-19 shots and those that don't, and the gap has widened as some wealthier countries have begun distributing third doses.

Rahm Emanuel questioned on murder of Laquan McDonald in confirmation hearing

Rahm Emanuel during a Senate Foreign Relations Committee confirmation hearing on Oct. 20. Photo: Sarah Silbiger/Bloomberg via Getty Images

Former Chicago Mayor Rahm Emanuel spoke about the murder of Laquan McDonald during his Senate confirmation hearing Wednesday to become the U.S. ambassador to Japan, saying that "there's not a day or a week that has gone by in the last seven years I haven't thought about this."

Catch up quick: McDonald was a Black teenager who was fatally shot 16 times by Chicago police during Emanuel's tenure as the city's mayor. The 2014 shooting triggered massive protests, both because of its nature and the fact that the officers' body-cam footage was concealed for years.

3 hours ago - World

Biden's ambassador nominee: "China is not an Olympian power"

Nick Burns testifying before the Senate Foreign Relations Committee. Photo: Sarah Silbiger/Bloomberg via Getty Images

President Biden's nominee to serve as ambassador to China delivered a stark assessment of the challenges the U.S. faces in confronting Beijing, but stressed that the rising superpower is "not all-powerful" and the West retains "substantial" advantages.

The big picture: Nicholas Burns, a retired career diplomat and former U.S. ambassador to NATO, used his confirmation hearing Wednesday to echo the growing bipartisan consensus that China poses "the greatest threat to the security of our country and the democratic world" in the 21st century.